Verve Expands Leadership Team with Appointment of Frederick T. Fiedorek, M.D., as Chief Medical Officer
18 Settembre 2023 - 12:30PM
Verve Therapeutics, a clinical-stage biotechnology company
pioneering a new approach to the care of cardiovascular disease
with single-course gene editing medicines, today announced the
appointment of Frederick “Fred” T. Fiedorek, M.D., as chief medical
officer (CMO). Andrew Bellinger, M.D., Ph.D., the current chief
scientific officer (CSO) and CMO, will transition to the role of
CSO.
“We are excited by the continued expansion of the Verve team and
the execution of a plan to become a multi-product clinical-stage
company,” said Sekar Kathiresan, M.D., co-founder and chief
executive officer of Verve. “Our heart-1 clinical trial is well
underway, with multiple additional trials planned in 2024 and
beyond, and we have a robust research effort to fuel pipeline
expansion and progress our partner programs. Now is the right time
to split the CMO and CSO roles with two, complementary industry
leaders. Verve’s tremendous progress over the last five years has
been made possible by Andrew’s significant contributions in his
joint role. He will continue to lead the growth of our portfolio as
CSO and be a key collaborator to Fred to inform our clinical and
regulatory strategies. Fred’s deep cardiology experience and more
than 20 years of clinical development and regulatory expertise in
the biopharma industry will be instrumental as we look to start
additional trials that bring more programs into the clinic. I am
thrilled by the talent of this team and our ability to execute our
mission.”
Dr. Bellinger noted, “We are pleased to welcome Fred to the team
during such an exciting time for the organization. This appointment
reflects our conviction in the global clinical development programs
at Verve and in the potential for in vivo gene editing to transform
the treatment of cardiovascular disease.”
“It is an amazing opportunity to join a company with such a bold
vision to change the treatment paradigm for cardiovascular
disease,” said Dr. Fiedorek. “The unmet needs in this therapeutic
area are significant, and I am excited to partner with this
impressive team and to contribute to the advancement of a pipeline
of single-course gene editing medicines that have transformational
potential.”
Dr. Fiedorek has more than 20 years of experience in clinical
development and leadership, primarily in therapeutic areas such as
diabetes, cardiovascular disease and endocrine/metabolic diseases.
Prior to Verve, he held CMO roles at Rhythm Pharmaceuticals,
Intarcia Therapeutics and a stealth company within Atlas Venture.
In addition, Dr. Fiedorek served as a senior advisor to Foresite
Capital Management. Prior to these roles, he spent 13 years at
Bristol-Myers Squibb (BMS), where he was most recently senior vice
president, head of cardiovascular and metabolic development
responsible for leading Phase 2 through Phase 4 global development
for the cardiovascular and metabolic therapeutic areas. Under his
leadership, several new medicines achieved successful marketing
authorization, including Eliquis® (apixaban), Farxiga®
(dapagliflozin), Onglyza® (saxagliptin) and Myalept® (metreleptin).
Prior to BMS, Dr. Fiedorek was international project leader for
metabolic drug development at Glaxo-Wellcome. He received an M.D.
from Harvard Medical School and trained in internal medicine and
endocrinology and metabolism at Washington University School
of Medicine in St. Louis. He also served on the faculty of the
University of North Carolina School of Medicine.
About Verve Therapeutics Verve
Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage genetic
medicines company pioneering a new approach to the care of
cardiovascular disease, potentially transforming treatment from
chronic management to single-course gene editing medicines. The
company’s initial three programs – VERVE-101, VERVE-102, and
VERVE-201 – target genes that have been extensively validated as
targets for lowering low-density lipoprotein cholesterol (LDL-C), a
root cause of cardiovascular disease. VERVE-101 and VERVE-102 are
designed to permanently turn off the PCSK9 gene in the liver and
are being developed initially for heterozygous familial
hypercholesterolemia (HeFH) and ultimately to treat atherosclerotic
cardiovascular disease (ASCVD) patients not at goal on oral
therapy. VERVE-201 is designed to permanently turn off the ANGPTL3
gene in the liver and is initially being developed for homozygous
familial hypercholesterolemia (HoFH) and ultimately to treat
patients with refractory hypercholesterolemia. For more
information, please visit www.VerveTx.com.
Cautionary Note Regarding Forward Looking
StatementsThis press release contains “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995 that involve substantial risks and
uncertainties, including statements regarding the initiation, and
timing, of the Company’s planned and future clinical trials and the
therapeutic potential of the company’s programs. All statements,
other than statements of historical facts, contained in this press
release, including statements regarding the company’s strategy,
future operations, future financial position, prospects, plans and
objectives of management, are forward-looking statements. The words
“anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,”
“intend,” “may,” “plan,” “potential,” “predict,” “project,”
“should,” “target,” “will,” “would” and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Any
forward-looking statements are based on management’s current
expectations of future events and are subject to a number of risks
and uncertainties that could cause actual results to differ
materially and adversely from those set forth in, or implied by,
such forward-looking statements. These risks and uncertainties
include, but are not limited to, risks associated with the
company’s limited operating history; the company’s ability to
timely submit and receive approvals of regulatory applications for
its product candidates; advance its product candidates in clinical
trials; initiate, enroll and complete its ongoing and future
clinical trials on the timeline expected or at all; correctly
estimate the potential patient population and/or market for the
company’s product candidates; replicate in clinical trials positive
results found in preclinical studies and/or earlier-stage clinical
trials of VERVE-101, VERVE-102, and VERVE-201; advance the
development of its product candidates under the timelines it
anticipates in current and future clinical trials; obtain, maintain
or protect intellectual property rights related to its product
candidates; manage expenses; and raise the substantial additional
capital needed to achieve its business objectives. For a discussion
of other risks and uncertainties, and other important factors, any
of which could cause the company’s actual results to differ from
those contained in the forward-looking statements, see the “Risk
Factors” section, as well as discussions of potential risks,
uncertainties and other important factors, in the company’s most
recent filings with the Securities and Exchange Commission and in
other filings that the company makes with the Securities and
Exchange Commission in the future. In addition, the forward-looking
statements included in this press release represent the company’s
views as of the date hereof and should not be relied upon as
representing the company’s views as of any date subsequent to the
date hereof. The company anticipates that subsequent events and
developments will cause the company’s views to change. However,
while the company may elect to update these forward-looking
statements at some point in the future, the company specifically
disclaims any obligation to do so.
Investor ContactJen RobinsonVerve Therapeutics,
Inc.jrobinson@vervetx.com
Media ContactDan Budwick1ABdan@1abmedia.com
Grafico Azioni Verve Therapeutics (NASDAQ:VERV)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Verve Therapeutics (NASDAQ:VERV)
Storico
Da Giu 2023 a Giu 2024